[Detection and significance of @entity470 mutation in esophageal, esophagogastric junction and XXXX ].

@entity1 @entity470 @entity5 @entity957 @entity418 @entity669 @entity356
OBJECTIVE: @entity669 kinase inhibitors (TKIs) of the @entity470 ( @entity470 ) have been reported to be effective in the treatment of esophageal and esophagogastric junction @entity5 . The aim of this study was to detect the frequency of @entity470 mutation and expression in Chinese @entity1 with esophageal, esophagogastric junction and @entity356 , and to clarify the value of @entity470 mutation and expression in predicting the efficacy of TKI in the treatment of these @entity5 . METHODS: In this study, 180 @entity5 samples with histologically confirmed @entity418 (39 cases), @entity5 of the esophagogastric junction (92 cases) and @entity356 (49 cases) were collected. Twenty-nine different @entity470 mutations in exons 18-21 were assessed by real-time PCR-optimized oligonucleotide probe method. @entity470 protein expression was evaluated by immunohistochemistry (IHC) in 89 @entity5 samples. RESULTS: The mutation analysis for @entity470 (exons 18-21) showed no mutations in any of the hotspots of the gene in the 180 @entity5 samples analyzed. @entity470 expression was negative in 12 @entity5 samples, 1+ in 31 @entity5 samples, 2+ in 24 @entity5 samples, and 3+ in 22 @entity5 samples. @entity470 expression was 2+ or 3+ in 12 (92.3%) of the 13 esophageal @entity957 , 29 (47.5%) of the 61 esophagogastric junction @entity5 , and 5 (33.3%) of the 15 @entity356 . CONCLUSIONS: Our results indicate that @entity470 mutation in exons 18-21 is absent in the examined samples of esophageal, esophagogastric junction and @entity356 . More studies are warranted to explore the predictive biological markers for the therapeutic response to @entity470 TKI.
